An invasive treatment called “bacteria vaginitis” has been successfully used in humans to treat bacterial vaginas, and it could help other people with the condition as well.
Researchers at the University of California, San Francisco and the University at Buffalo have found that the antibiotic, sold under the brand name Listeria monocytogenes, works for treating bacterial vaginis, and they hope it could eventually be used to treat other diseases as well, such as diabetes, Alzheimer’s and asthma.
The treatment was developed in a study of patients with bacterial vaginositis, which causes inflammation of the vagina and anus.
Researchers found that using the antibiotic was successful in both reducing inflammation and preventing symptoms of the condition, including cramping, vaginal discharge, bloating and pain.
This is important because some bacterial vagins are resistant to the drug, and the new treatment does not require a separate antibiotic treatment.
“If you’ve been experiencing any of these symptoms, you may not be able to control your symptoms,” said lead author Jules Jorgensen, an assistant professor of microbiology and immunology and of surgery at UC San Francisco.
“We found that people who were already taking a bacterial vaginocephaly drug or other antibiotic, did not experience any side effects, and we also did not see any benefit from a different antibiotic treatment.”
Bacterial vaginis are a type of infection that can be caused by certain types of bacteria, such for example, Candida, and can affect the vaginal lining.
Symptoms can include cramping or vaginal discharge and are typically more severe in women.
The condition affects about 1 in 5 women in the United States, but can be more common in older women and women who have certain medical conditions.
It can cause painful bloating or other symptoms, which can also make it difficult to urinate, eat or feel full.
Treatment for bacterial vagini can be expensive, and doctors can often prescribe antibiotics that can make it more difficult to stop the infection.
But the study shows that Listerium monocytones can be effective for treating the condition.
“The antibiotic can reduce inflammation and improve the symptoms, but it doesn’t require a different treatment,” Jorgenson said.
“It’s a very inexpensive treatment, which is very important for the millions of women in need of this treatment.”
He said that although the results of this study were not promising, the findings could be helpful for future studies.
“This is not a panacea for all bacterial vaginalis, and people can still benefit from this,” Jorsen said.
In addition to the potential for the drug to help people with bacterial infections, the treatment could also help treat other conditions.
A similar treatment called vaginal herpes was used in the 1980s and 1990s, but because it was not effective, researchers decided to develop a bacterial vulvovaginal infection treatment.
This type of bacterial vaginic infection affects about one in 30 women, but is often difficult to treat, and has a high risk of complications, such from infection.
The drug Lactobacillus acidophilus is used to cure bacterial vulvar infections.
In the study published in the journal JAMA Internal Medicine, Jorgensons team studied women with bacterial vulva infections and compared them with women who had been treated with other treatments.
The researchers found that women who were treated with antibiotics had fewer vaginal lesions than those who had not.
“For women who didn’t have symptoms, the antibiotics were associated with lower counts of lesions in their vulvaginitis,” Jores said.
However, they found no difference in the rates of bacterial vulvas infections between the two groups.
“Overall, the results suggest that a novel antibiotic, Lactococcus lactis, may have potential for treating bacteria vaginas,” Jorge said.
The research was supported by the National Institutes of Health (grants R01-AI089613, R01, DK01-014566 and R01AG02398) and the American Academy of Family Physicians, the American Society of Clinical Microbiology, the National Institute of Allergy and Infectious Diseases, the International Federation of Microbiology and Infection Control, the Association for Infectious Disease Research and Education and the New York City Department of Health.